Mono PharmacareNSE:MONOPHARMA -1.79%9 ROE % is 0.13% as of Sep. 2025, which is 99% below its 10-year median of 10.42. GuruFocus rates NSE:MONOPHARMA with a GF Score™ of 9/100. The stock has 6 warning signs investors should review. Among 623 Healthcare Providers & Services companies, Mono Pharmacare ranks worse than 59.87% on this metric.
The historical rank and industry rank for Mono Pharmacare's ROE % or its related term are showing as below:
NSE:MONOPHARMA'
s ROE % Range Over the Past 10 Years
Min: 2.57 Med: 10.42 Max: 13.95
Current: 2.64
During the past 5 years, Mono Pharmacare's highest ROE % was 13.95%. The lowest was 2.57%. And the median was 10.42%.
NSE:MONOPHARMA's ROE % is ranked worse than 59.87% of 623
companies
in the Healthcare Providers & Services industry
Industry Median: 5.86
vs NSE:MONOPHARMA: 2.64
ROE % measures the rate of return on the ownership interest (shareholder's equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' equity (also known as net assets or assets minus liabilities). ROE % shows how well a company uses investment funds to generate earnings growth. ROE %s between 15% and 20% are considered desirable.
The factors that affect a company's ROE % can be illustrated with the three-step DuPont Analysis:
Note:
The net income data used here is two times the semi-annual (Sep. 2025) net income data. The Revenue data used here is two times the semi-annual (Sep. 2025) revenue data. The same rule applies to Pre-Tax Income and Operating Income.
* In the five-step DuPont Analysis, Operating Income is only available for non-financial companies. Thus, for Insurance companies, we use EBIT as a substitution of Operating Income. For Banks, both Operating Income and EBIT is unavailable. Thus we combined Interest Burden and Operating Margin % into Pretax Margin %, and the DuPont Analysis is divided into four components instead.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Net Income is used.
Because a company can increase its ROE % by having more financial leverage, it is important to watch the equity multiplier when investing in high ROE % companies. Like ROA %, ROE % is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.
Asset light businesses require very few assets to generate very high earnings. Their ROE %s can be extremely high.
Mono Pharmacare ROE % Related Terms
Mono Pharmacare ROE % Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's ROE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Pharmaceutical Retailers subindustry, Mono Pharmacare's ROE %, along with its competitors' market caps and ROE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mono Pharmacare ROE % vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, Mono Pharmacare's ROE % distribution charts can be found below:
* The bar in red indicates where Mono Pharmacare's ROE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of annual ROE %, the net income of the last fiscal year and the average total shareholder equity over the fiscal year are used. In calculating the quarterly data,
the net income data used here is two times the semi-annual (Sep. 2025) net income data.
ROE % is displayed in the 30-year financial page.
Mono Pharmacare (NSE:MONOPHARMA) has a ROE % of 0.13% as of Sep. 2025. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Mono Pharmacare and its competitors. This is 99% below median its historical median of 10.42. Over the past decade, Mono Pharmacare's ROE % has ranged from 2.57 to 13.95. According to the industry distribution chart, Mono Pharmacare ranks #373 out of 623 companies in the Healthcare Providers & Services industry, placing it in the top 59.9%.
Is Mono Pharmacare's ROE % too high?
Mono Pharmacare's current ROE % of 0.13% is 99% below median its 10-year median of 10.42. Over the past 10 years, this metric has ranged from a low of 2.57 to a high of 13.95. The Healthcare Providers & Services industry median ROE % is 5.86. Mono Pharmacare's value of 0.13% is 97.8% below this industry median. Based on the distribution chart, Mono Pharmacare ranks #373 out of 623 companies in the Healthcare Providers & Services industry, which is below the industry midpoint. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's ROE % compare to competitors?
According to the Healthcare Providers & Services industry distribution chart, Mono Pharmacare ranks #373 out of 623 companies for ROE %. This places Mono Pharmacare in the lower half of its industry. The industry median ROE % is 5.86. Mono Pharmacare's value of 0.13% is 97.8% below this benchmark. Historically, Mono Pharmacare's own ROE % has ranged from 2.57 to 13.95 over the past decade. While the company's 10-year median is 10.42 vs. the industry median of 5.86, Mono Pharmacare has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % for a Healthcare Providers & Services company?
The median ROE % among Healthcare Providers & Services companies is 5.86, based on 623 companies in the industry. Companies in the top quartile (top 25%) have a ROE % significantly above this median, while those in the bottom quartile fall well below. However, ROE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Mono Pharmacare's current ROE % of 0.13% is 97.8% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % mean?
A high ROE % can signal that a stock is expensive relative to its fundamentals. Return on equity is the ratio of current-period net income to average two-period total equity. View historical data on Mono Pharmacare and its competitors. For the Healthcare Providers & Services industry, the median ROE % is 5.86 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mono Pharmacare's current ROE % is 0.13%, which is 99% below median its own 10-year median of 10.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current ROE % of 0.13%. The current ROE % is 0.13%, which is 99% below median its 10-year median of 10.42 and 97.8% below the Healthcare Providers & Services industry median of 5.86. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % calculated?
ROE % is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current ROE % is 0.13% as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
ROE % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
